Company intelligence / Profile preview

Giant

Ownership: Private
Development stage: Other

Overview

Giant Bio Technology has developed proprietary technologies for antibiotic-free disease prevention and detection in aquaculture. Their flagship platform, Herbmedotcin™, amplifies the antibacterial effect of plant-derived compounds by 2,500 times using nanotechnology. The company also offers advanced biosecurity monitoring solutions and a unique probiotic/postbiotic product line designed to improve gut health in aquatic animals[1].

Therapeutic areas: Infectious Diseases
Modalities: ProbioticPostbioticPhytogenic compound-based therapyNanotechnology-enhanced natural products
Industry: Veterinary

Partnerships

Supported by Taiwan Ministry of Science and Technology's Innovation & Entrepreneurship Program[1]

Beyond the preview

Go deeper on Giant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Giant.

Explore the full profile